HISTORY
Launched in September 2007, Vivia Biotech raised €4 M seed capital with VC Funds, a record for the first Spanish biotech company reaching such a seed capital investment in the industry.
Vivia Biotech is worldwide pioneer in the “screening” and profiling of thousands of drugs on a patient blood sample, thanks to the ExviTech technological platform.
This platform, ExviTech, developed originally at USA by an American team moved to Spain to start up Vivia, a pioneer company with international recognition that has been able to take scientific advantage at Spain's world leadership in terms of altruistic donation of organs and samples for research.
Vivia is successfully developing its intensive project on R & D + i. In a short period of time, we have advanced our research in finding new solutions that are less aggressive in the treatment of hematologic malignancies and customization of treatment of these diseases to the patient’s individual characteristics. The company has reached two collaboration R & D + I agreements with big Pharma with USA headquarters.
Vivia´s team is formed by 28 highgly qualified professionals, dedicated to improving the life expectancy and quality of patients with the diseases investigated.
